Monopar Therapeutics (MNPR) Short Interest Ratio & Short Volume

Short interest is the volume of Monopar Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 31st, investors have sold 170,500 shares of MNPR short. 2.29% of Monopar Therapeutics' shares are currently sold short. Learn More on Monopar Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.29% of Monopar Therapeutics' floating shares are currently sold short.

Monopar Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 170,500 shares, a drop of 25.7% from the previous total of 229,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Monopar Therapeutics currently has issued a total of 17,450,000 shares. Some of Monopar Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Monopar Therapeutics currently has a public float of 7,450,000 shares.

2.29% of Monopar Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Monopar Therapeutics: Eterna Therapeutics Inc. (1.42%), Galera Therapeutics, Inc. (4.07%), Guardion Health Sciences, Inc. (13.71%), Purple Biotech Ltd. (0.88%), Moleculin Biotech, Inc. (2.09%), Imunon, Inc. (4.75%), Elevai Labs, Inc. (0.19%), Alterity Therapeutics Limited (0.28%), RedHill Biopharma Ltd. (3.07%), MIRA Pharmaceuticals, Inc. (0.71%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling MNPR is an investing strategy that aims to generate trading profit from Monopar Therapeutics as its price is falling. MNPR shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Monopar Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MNPR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MNPR, twice per month. The most recent reporting period available is March, 31 2024.